<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/8BF06BDD-49D2-4636-A041-C620A551A377"><gtr:id>8BF06BDD-49D2-4636-A041-C620A551A377</gtr:id><gtr:name>Curapel (Scotland) Limited</gtr:name><gtr:address><gtr:line1>272, Bath Street</gtr:line1><gtr:city>Glasgow</gtr:city><gtr:postCode>G2 4JR</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8BF06BDD-49D2-4636-A041-C620A551A377" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>8BF06BDD-49D2-4636-A041-C620A551A377</gtr:id><gtr:name>Curapel (Scotland) Limited</gtr:name><gtr:address><gtr:line1>272, Bath Street</gtr:line1><gtr:city>Glasgow</gtr:city><gtr:postCode>G2 4JR</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>184416.0</gtr:offerGrant><gtr:projectCost>263452.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0FA38921-315D-4BF2-8621-1D92FB334E8C"><gtr:id>0FA38921-315D-4BF2-8621-1D92FB334E8C</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>Gibbs</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=102942"><gtr:id>8CC8951E-0F88-4CD9-B24D-309004BBE08D</gtr:id><gtr:title>DEVELOPING A SAFE, NUTRITIONAL SUPPLEMENT FOR CHILDREN WITH DRY SKIN &amp;amp; ECZEMA</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>102942</gtr:grantReference><gtr:abstractText>Curapel&amp;reg; is a skin healthcare company that is developing patented products to help people with common, chronic and distressing skin conditions such as eczema and psoriasis. All Curapel's products contain natural and safe active ingredients which were identified by researchers at the the University of Manchester. The Curapel Philosophy is simple, we intend to develop successful products based on these technologies that work effectively with skin biology to 'Heal Skin Safely'. Eczema is one of the most common skin conditions that is six times more common in young children aged 1-5 years (~20%) than in adults (~3%). Unfortunately, current products for this distressing condition either just soothe the skin (emollients) or are medicines such as steroid creams that have extremely harsh side effects, especially when used by young children suffering from a chronic skin condition Curapel is now developing HISTIMEX as a safe, easy to use, once a day, oral nutritional supplement that provides a vital building block to restore a healthy skin barrier across the whole body. HISTIMEX has been tested in adults and has a similar effect as a middle-strength steroid cream but without any of the side effects. Curapel is now asking Innovate UK to help fund the testing of a new young child-friendly version of HISTIMEX in a clinical study in 1-5 year old children with eczema. When we have shown the effectiveness of this new children's HISTIMEX, we aim to launch it in 2017 as a safe product for young eczema sufferers.</gtr:abstractText><gtr:fund><gtr:end>2018-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>184416</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">102942</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>